706 related articles for article (PubMed ID: 22355058)
1. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
Sansone P; Bromberg J
J Clin Oncol; 2012 Mar; 30(9):1005-14. PubMed ID: 22355058
[TBL] [Abstract][Full Text] [Related]
2. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
3. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
Yang X; Tang Z; Zhang P; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
[TBL] [Abstract][Full Text] [Related]
5. Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.
Durham GA; Williams JJL; Nasim MT; Palmer TM
Trends Pharmacol Sci; 2019 May; 40(5):298-308. PubMed ID: 30948191
[TBL] [Abstract][Full Text] [Related]
6. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
Ferrajoli A; Faderl S; Ravandi F; Estrov Z
Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
[TBL] [Abstract][Full Text] [Related]
7. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
8. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
[TBL] [Abstract][Full Text] [Related]
9. Manipulation of JAK/STAT Signalling by High-Risk HPVs: Potential Therapeutic Targets for HPV-Associated Malignancies.
Morgan EL; Macdonald A
Viruses; 2020 Sep; 12(9):. PubMed ID: 32899142
[TBL] [Abstract][Full Text] [Related]
10. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
Venugopal S; Bar-Natan M; Mascarenhas JO
Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
[TBL] [Abstract][Full Text] [Related]
11. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
12. [Advances in study on drugs targeting the JAKs/STATs passway].
Sheng L; Li Y
Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):162-5. PubMed ID: 16850627
[No Abstract] [Full Text] [Related]
13. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
[TBL] [Abstract][Full Text] [Related]
14. Targeting the JAK-STAT pathway in the treatment of 'Th2-high' severe asthma.
Vale K
Future Med Chem; 2016; 8(4):405-19. PubMed ID: 26934038
[TBL] [Abstract][Full Text] [Related]
15. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
[TBL] [Abstract][Full Text] [Related]
16. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
17. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.
Waldmann TA; Chen J
Annu Rev Immunol; 2017 Apr; 35():533-550. PubMed ID: 28182501
[TBL] [Abstract][Full Text] [Related]
18. Dynamics and non-canonical aspects of JAK/STAT signalling.
Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
20. Small molecule drug discovery targeting the JAK-STAT pathway.
Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
